{"id":"a7211cc4b547","type":"article","url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","title":"NHLBI-workshop: bloeddrukmeting verfijnen door de hele levensloop heen — knelpunten en kansen","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2026.02.5124","source_url":"https://doi.org/10.1016/j.jacc.2026.02.5124","authors":["Marwah Abdalla","Stephen P Juraschek","Italo Biaggioni","C Barrett Bowling","Ravi C Balijepalli","Tammy M Brady","Adam P Bress","Robert D Brook","Jordana B Cohen","Yvonne Commodore-Mensah","Richard A Dart","Patrice Desvigne-Nickens","Paul Drawz","Keith C Ferdinand","Joseph T Flynn","Kathryn Foti","Beverley B Green","Kara K Hoppe","Kate Kirley","Lewis Lipsitz","Young S Oh","Jesus D Melgarejo","Ramakrishna Mukkamala","Paul Muntner","Joseph Ravenell","Daichi Shimbo","Andrew M South","Raymond R Townsend","Jasmina Varagic","Hilary K Wall","Paul Wang","Paula Einhorn","Michael Wolz"],"significance":7,"published":"2026-06-23","source_date":"2026-05-12","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"Report from a 2-day workshop convened by the US National Heart, Lung, and Blood Institute (NHLBI, December 2024) on the state of blood pressure assessment. Hypertension remains the principal modifiable cardiovascular risk factor, yet adequate characterisation of BP is challenging due to lifespan, comorbidity, and environmental influences. Uncertainty in BP measurement contributes to underdiagnosis, undertreatment, and preventable morbidity/mortality. Recent technological developments — home and ambulatory monitoring, wearables — enable richer BP characterisation that could dramatically improve hypertension management and cardiovascular risk reduction. The report summarises the latest evidence, identifies knowledge gaps, and sets research and practice priorities for advancing BP assessment.","created":"2026-07-03T10:33:06Z","updated":"2026-07-03T18:39:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Rapport van een 2-daagse workshop van het US National Heart, Lung, and Blood Institute (NHLBI, december 2024) over de stand van zaken in bloeddruk-assessment. Hypertensie blijft de belangrijkste beïnvloedbare risicofactor voor cardiovasculaire ziekte, maar adequate karakterisering van bloeddruk is uitdagend door invloeden van levensfase, comorbiditeit en omgeving. Onzekerheid in BD-meting draagt bij aan onderdiagnose, onderbehandeling en vermijdbare morbiditeit/mortaliteit. Recente technologische ontwikkelingen — thuismeting, ambulante meting, draagbare meters — maken een vollediger BD-profiel mogelijk en kunnen het hypertensiebeleid en CV-risicoreductie dramatisch verbeteren. Het rapport vat het laatste bewijs samen, identificeert kennis-lacunes en formuleert onderzoeks- en zorgprioriteiten voor verbetering van BD-assessment.","abstract_original":"Hypertension is a modifiable risk factor for cardiovascular disease (CVD) and its prevalence is high in the United States and worldwide. Adequate characterization of blood pressure (BP) is essential for the diagnosis and management of hypertension. However, BP assessment can be challenging because of the unique influences across the lifespan, disease conditions, and physical environmental context. Moreover, complex uncertainties in BP assessment may contribute to underdiagnosis, undertreatment, and preventable morbidity and mortality. Recent advances in BP measurement devices have enabled comprehensive characterization of BP that could dramatically change how hypertension is managed to optimize CVD risk reduction, avoid complications of low BP, and improve hypertension control rates. To address the rapidly evolving landscape in BP assessment, the National Heart, Lung, and Blood Institute of the U.S. National Institutes of Health convened a 2-day workshop of clinicians and researchers in December 2024. The present report summarizes the topics presented and discussed during the meeting, which focused on the latest evidence on BP assessment as well as obstacles and knowledge gaps to be addressed to advance BP assessment in clinical practice and research."}